Shanghai Jahwa(600315)

Search documents
上海家化(600315) - 上海家化2024年审计报告
2025-04-24 13:05
上海家化联合股份有限公司 2024 年度财务报表及审计报告 the first and 上海家化联合股份有限公司 2024 年度财务报表及审计报告 | 内容 | 页码 | | --- | --- | | 审计报告 | 1 - 8 | | 2024 年度财务报表 | | | 合并及公司资产负债表 | 1 | | 合并及公司利润表 | 2 | | 合并及公司现金流量表 | 3 | | 合并股东权益变动表 | র্ব | | 公司股东权益变动表 | 5 | | 财务报表附注 | 6 - 133 | | 补充资料 | 1 | 普华永道 审计报告 普华永道中天审字(2025)第 10022 号 (第一页,共八页) 上海家化联合股份有限公司全体股东: 一、审计意见 · (一)我们审计的内容 我们审计了上海家化联合股份有限公司(以下简称"上海家化")的财务 报表,包括 2024年 12月 31 日的合并及公司资产负债表,2024年度的合并 及公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及财 务报表附注。 (二)我们的意见 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编 制,公允反映了上海家化 ...
上海家化(600315) - 上海家化2024年度内部控制审计报告
2025-04-24 13:05
2024 年度内部控制审计报告 . 普华永道 上海家化联合股份有限公司 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发 表审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制审计报告 普华永道中天特审字(2025)第 0932 号 (第一页,共二页) 上海家化联合股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求, 我们审计了上海家化联合股份有限公司("贵公司")2024年12月31日的财务 报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控 制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是贵公 司董事会的责任。 二、注册会计师的责任 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由 于情况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度 降低,根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 普华永道中天会计师事务所(特殊普通合伙) 中国上海市黄浦区湖滨路202号领展企业广场2座普华永道中 ...
上海家化(600315) - 上海家化独立董事2024年度述职报告(冯国华)
2025-04-24 12:58
上海家化联合股份有限公司 独立董事述职报告 2024年,我通过会谈沟通、阅读资料、现场办公等方式积极履行独立董事职 责,对董事会将要讨论的重大事项要求公司相关部门提供详实的决策依据,对每 次董事会和董事会专门委员会的议案材料,我都认真阅读、仔细研究。参会过程 中认真听取管理层的汇报,积极参与讨论,充分运用我的专业知识,发表自己的 意见和建议。我对董事会的全部议案进行了审慎细致的审议,并慎重投票。 二、参与董事会专门委员会、独立董事专门会议工作情况 上海家化联合股份有限公司 2024 年度独立董事述职报告 作为上海家化联合股份有限公司(以下简称"公司")的独立董事,我依照 《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指引第1号 ——规范运作》等相关规则,通过董事会专门委员会、独立董事专门会议、董事 会等方式,独立、公正地履行职责,提升董事会决策水平,保护中小股东合法权 益。 本人冯国华:本科,拥有丰富的消费品行业经验。曾任金蝶国际软件集团有 限公司总裁、中国惠普有限公司副总裁、国际商业机器(中国)有限公司副总裁 /高级合伙人、汉能控股集团高级副总裁、微软(中国)有限公司副总裁、敏华 控股有限公司 ...
上海家化(600315) - 上海家化独立董事2024年度述职报告(夏海通)
2025-04-24 12:58
上海家化联合股份有限公司 独立董事述职报告 上海家化联合股份有限公司 2024 年度独立董事述职报告 作为上海家化联合股份有限公司(以下简称"公司")的独立董事,我依照 《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指引第1号 ——规范运作》等相关规则,通过董事会专门委员会、独立董事专门会议、董事 会等方式,独立、公正地履行职责,提升董事会决策水平,保护中小股东合法权 益。 本人夏海通:硕士。曾任蒙牛乳业(集团)股份有限公司营销副总经理,现 任朴诚乳业(集团)有限公司创始人、董事长兼首席执行官,简爱酸奶品牌创始 人、本公司独立董事。 现将2024年度履职情况汇报如下: 一、全年出席董事会、股东大会情况 2024年,公司共举行1次股东大会,8次董事会、6次审计与风险管理委员会 会议、4次薪酬与考核委员会会议,3次提名委员会会议,我上任后均亲自出席。 2024年,我通过会谈沟通、阅读资料等方式积极履行独立董事职责,对董事 会将要讨论的重大事项要求公司相关部门提供详实的决策依据,对每次董事会和 董事会专门委员会的议案材料,我都认真阅读、仔细研究。参会过程中认真听取 管理层的汇报,积极参与讨论,充分运用 ...
上海家化(600315) - 上海家化独立董事2024年度述职报告(肖立荣)
2025-04-24 12:58
上海家化联合股份有限公司 独立董事述职报告 上海家化联合股份有限公司 2024 年度独立董事述职报告 作为上海家化联合股份有限公司(以下简称"公司")的独立董事,我依照 《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指引第1号 ——规范运作》等相关规则,通过董事会专门委员会、独立董事专门会议、董事 会等方式,独立、公正地履行职责,提升董事会决策水平,保护中小股东合法权 益。 本人肖立荣:硕士,高级会计师。曾任江西财经大学讲师、华润深国投信托 有限公司财务总监、华润(集团)有限公司财务部副总经理。现任本公司独立董 事。 现将2024年度履职情况汇报如下: 一、全年出席董事会、股东大会情况 2024年,公司共举行1次股东大会,8次董事会、6次审计与风险管理委员会 会议、3次提名委员会会议,我均亲自出席。 2024年,我通过会谈沟通、阅读资料等方式积极履行独立董事职责,对董事 会将要讨论的重大事项要求公司相关部门提供详实的决策依据,对每次董事会和 董事会专门委员会的议案材料,我都认真阅读、仔细研究。参会过程中认真听取 管理层的汇报,积极参与讨论,充分运用我的专业知识,发表自己的意见和建议。 我对董事会 ...
上海家化(600315) - 上海家化董事会关于独立董事独立性情况的专项评估意见
2025-04-24 12:58
上海家化联合股份有限公司 独立董事独立性 上海家化联合股份有限公司董事会 关于 2024 年度独立董事独立性情况的专项评估意见 根据《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》、《上 海证券交易所上市公司自律监管指引第 1 号--规范运作》等要求,公司董事会 就公司在任独立董事肖立荣、冯国华、夏海通的独立性情况进行评估并出具如下 专项意见: 经核查公司独立董事肖立荣、冯国华、夏海通的任职经历以及签署的相关自 查文件,上述人员未在公司担任除独立董事以外的任何职务,也未在公司主要股 东公司担任任何职务,与公司以及主要股东之间不存在利害关系或其他可能妨碍 其进行独立客观判断的关系,因此,公司独立董事符合《上市公司独立董事管理 办法》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》中对独立 董事独立性的相关要求。 上海家化联合股份有限公司董事会 2025年4月23日 ...
上海家化(600315) - 上海家化长期激励基金管理办法
2025-04-24 12:58
证券简称:上海家化 证券代码:600315 上海家化联合股份有限公司 长期激励基金管理办法 二〇二五年四月 声明 上海家化联合股份有限公司(以下简称"公司")及董事会全体成员保证《公司 长期激励基金管理办法》(以下简称"本管理办法")不存在虚假记载、误导性陈述 或重大遗漏,并对其真实性、准确性、完整性承担法律责任。 特别提示 1、本管理办法系依据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")等有关法律、行政法规, 综合考虑公司长期员工激励计划而制定。 2、本管理办法覆盖的对象范围包括公司高级管理人员,公司及子公司(全 资或控股,下同)的核心管理人员以及公司认定的应当予以激励的其他员工。 3、本管理办法从2025年度开始实施。如有特殊原因需要调整的,经股东大 会审批后予以调整。 2 长期激励基金管理办法 | | 声明 2 | | --- | --- | | | 特别提示 2 | | | 目录 3 | | 第一章 | 总则 4 | | 第二章 | 管理机构 5 | | 第三章 | 长期激励基金的计提 6 | | 第四章 | 长期激励基金的用途 8 | | ...
上海家化(600315) - 上海家化2025年员工持股计划管理办法
2025-04-24 12:58
上海家化联合股份有限公司 2025 年员工持股计划管理办法 第一章 总则 第一条 为规范上海家化联合股份有限公司(以下简称"上海家化"或"公司") 2025 年员工持股计划(以下简称"本持股计划")的实施,根据《中华人民共和 国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证 券法》")、《关于上市公司实施员工持股计划试点的指导意见》(以下简称"《指 导意见》")等相关法律、行政法规、规范性文件和《公司章程》、《上海家化联 合股份有限公司 2025 年员工持股计划(草案)》之规定,特制定《上海家化联合 股份有限公司 2025 年员工持股计划管理办法》(以下简称"本管理办法")。 第二章 本持股计划的制定 第二条 本持股计划的目的 公司依据《公司法》《证券法》《指导意见》等有关法律、行政法规、规章、 规范性文件和《公司章程》的规定,制定了本持股计划草案。 公司员工自愿、合法、合规地参与本持股计划,持有公司股票的目的在于建 立和完善员工、股东的利益共享机制,改善公司治理水平,提高职工的凝聚力和 公司竞争力,调动员工的积极性和创造性,促进公司长期、持续、健康发展。 第三条 本持股计划的基 ...
上海家化(600315) - 2024 Q4 - 年度财报
2025-04-24 12:25
Financial Performance - The net profit attributable to shareholders for 2024 is -833,092,522.20 CNY, a decrease of 266.60% compared to the previous year's profit of 500,049,003.38 CNY[6]. - Operating revenue for 2024 is 5,678,512,025.49 CNY, representing a 13.93% decline from 6,597,599,900.71 CNY in 2023[20]. - The basic earnings per share for 2024 is -1.24 CNY, a decrease of 265.33% compared to 0.75 CNY in 2023[21]. - The company's consolidated revenue for the reporting period was CNY 5.68 billion, a year-on-year decrease of 13.9%[30]. - The net profit attributable to shareholders for 2024 was CNY -830 million, a year-on-year decline of 266.6%[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -840 million, a year-on-year decrease of 366.4%[30]. - The company recognized an asset impairment provision of CNY 610 million related to goodwill from previous acquisitions of infant care and maternal feeding product businesses[30]. - The company reported a net loss of approximately CNY 714.30 million for the Abundant Merit Limited subsidiary, which focuses on infant feeding tools and care products[67]. Cash Flow and Assets - The net cash flow from operating activities increased to 273,196,710.98 CNY, a 164.86% rise from 103,147,826.31 CNY in 2023[20]. - Total assets decreased by 15.22% to 9,944,442,518.04 CNY from 11,729,795,966.33 CNY in 2023[20]. - The company's cash and cash equivalents decreased by 41.42% to 550,466,054.78, mainly due to increased cash outflows from investment and financing activities[63]. - Accounts receivable decreased by 33.30% to 865,815,125.09, attributed to strategic adjustments impacting current revenue[63]. - The company's goodwill decreased by 28.81% to approximately CNY 1.49 billion, mainly due to significant performance declines in overseas operations leading to impairment losses[64]. Strategic Adjustments and Market Challenges - The company faced significant challenges in overseas markets, including low birth rates and increased competition, impacting revenue and gross profit[22]. - Strategic adjustments, including reducing inventory in department stores and transitioning to a self-operated model for online distributors, negatively affected current revenue and profits[22]. - The company anticipates that the strategic adjustments will benefit its long-term sustainable development despite the short-term negative impacts[22]. - The company plans to enhance its R&D investment and focus on core markets such as the UK and the US to improve brand influence through precise marketing[32]. Revenue Breakdown - The personal care segment generated revenue of approximately ¥2.38 billion, with a gross margin of 63.59%, an increase of 2.57 percentage points year-over-year[51]. - The beauty segment reported revenue of approximately ¥1.05 billion, with a gross margin of 69.67%, a decrease of 2.68 percentage points year-over-year[51]. - The overseas revenue amounted to approximately ¥1.42 billion, with a gross margin of 48.32%, down by 3.02 percentage points year-over-year[52]. - Online sales contributed approximately ¥2.54 billion, with a gross margin of 63.53%, a decrease of 9.66% year-over-year[52]. - Offline sales were approximately ¥3.14 billion, with a gross margin of 52.78%, down by 16.97% year-over-year[52]. Research and Development - Research and development expenses increased by 3.1% to CNY 150 million[30]. - The company employed 201 R&D personnel, accounting for 4.66% of total employees, with a significant portion holding master's degrees[59]. - The company has developed a skin surface AGEs fluorescence probe for real-time, quantifiable detection of skin glycation products, enhancing its product offerings in skin health[79]. - The company launched new products including the Six God Deodorizing and Itch Relief Flower Water, featuring proprietary technology for odor removal and skin soothing[81]. Governance and Compliance - The board of directors consists of 7 members, including 3 independent non-executive directors, ensuring diverse expertise[113]. - The independent directors attended all 8 board meetings in 2024, demonstrating active participation in governance[114]. - The company has established a comprehensive risk management system, identifying key control points and enhancing internal control processes to prevent risks[120]. - The company has committed to addressing any potential conflicts of interest arising from related party transactions[124]. Sustainability and Social Responsibility - The company invested 3.6 million RMB in environmental protection during the reporting period[161]. - The company achieved significant energy savings through various measures, including a total of 1,190 MWh saved from air conditioning and wastewater treatment improvements[164]. - The company has engaged in various charitable activities, including donations to support autism rehabilitation and education[167]. - The company has a commitment to sustainable development, as detailed in its 2024 Sustainability Report available on the Shanghai Stock Exchange website[168]. Financial Products and Investments - The company has entrusted a total of 2,300,000,000.00 RMB in bank wealth management products, with an outstanding balance of 2,250,000,000.00 RMB[187]. - The company has multiple bank wealth management products with expected annualized returns ranging from 3,443,284.93 RMB to 10,681,565.75 RMB[187]. - The financial products are primarily funded through self-owned capital, reflecting a conservative funding strategy[188][189]. Employee and Management - The total number of employees in the parent company is 1,138, while the total number of employees in major subsidiaries is 3,173, resulting in a combined total of 4,311 employees[142]. - The company has a performance evaluation system that will be continuously optimized in 2024, linking variable compensation to company performance, departmental performance, and individual assessments[143]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 12.248 million yuan[130].
上海家化(600315) - 2025 Q1 - 季度财报
2025-04-24 12:25
Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,703,607,733.01, a decrease of 10.59% compared to CNY 1,905,398,114.42 in the same period last year[4] - Net profit attributable to shareholders was CNY 217,134,362.72, down 15.25% from CNY 256,207,190.53 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 34.49%, amounting to CNY 192,186,990.60 compared to CNY 293,382,590.79 in the previous year[4] - Basic and diluted earnings per share were both CNY 0.32, a decrease of 15.79% from CNY 0.38 in the previous year[5] - Operating profit for Q1 2025 was CNY 232,529,809.90, down 14.7% from CNY 272,485,558.68 in the same period last year[20] - The total comprehensive income for Q1 2025 was CNY 256,245,001.31, compared to CNY 230,653,584.01 in Q1 2024, reflecting a growth of 11.1%[21] Cash Flow and Assets - The net cash flow from operating activities increased by 7.96% to CNY 615,569,231.56, up from CNY 570,208,886.78 in the same period last year[4] - Cash and cash equivalents as of March 31, 2025, were RMB 642,789,403.39, up from RMB 550,466,054.78 at the end of 2024[13] - The net cash flow from operating activities in Q1 2025 was CNY 615,569,231.56, an increase of 7.9% compared to CNY 570,208,886.78 in Q1 2024[24] - The company reported a net cash outflow from investing activities of CNY -349,753,889.53 in Q1 2025, compared to CNY -5,279,450.36 in Q1 2024[24] - Cash and cash equivalents at the end of Q1 2025 totaled CNY 635,037,361.20, down from CNY 1,332,084,785.93 at the end of Q1 2024[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,415,987,751.19, an increase of 4.74% from CNY 9,944,442,518.04 at the end of the previous year[5] - Total current assets amounted to RMB 5,322,361,912.63, slightly up from RMB 5,261,900,533.94 at the end of 2024[14] - Total non-current assets increased to RMB 5,093,625,838.56 from RMB 4,682,541,984.10 at the end of 2024[15] - Total liabilities increased to RMB 3,565,257,418.71 from RMB 3,252,691,647.92 at the end of 2024[15] - Shareholders' equity attributable to shareholders was CNY 6,850,730,332.48, up 2.38% from CNY 6,691,750,870.12 at the end of the previous year[5] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,276[9] - The company held 6,143,072 shares in its repurchase account, accounting for 0.91% of the total share capital[11] Costs and Expenses - Total operating costs for Q1 2025 were RMB 1,502,972,403.47, down 5.8% from RMB 1,595,257,754.22 in Q1 2024[19] - Operating costs included RMB 623,462,399.64 for cost of goods sold, a decrease from RMB 699,901,352.07 in the previous year[19] - The company incurred research and development expenses of CNY 38,739,667.60 in Q1 2025, an increase from CNY 34,862,844.43 in Q1 2024[20] Non-Recurring Items - Non-recurring gains and losses totaled CNY 24,947,372.12, after accounting for tax effects of CNY 3,980,758.19[7] - The decline in net profit was primarily due to adjustments in pricing strategies and inventory optimization, which affected revenue and gross profit margins[7] - The company reported a significant increase in other comprehensive income, totaling CNY 39,110,638.59 in Q1 2025, compared to a loss of CNY -25,553,606.52 in Q1 2024[20]